Accéder au contenu
Merck

Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic mice.

Microcirculation (New York, N.Y. : 1994) (2008-06-25)
Seungjun Lee, Norman R Harris
RÉSUMÉ

Reductions in retinal blood flow are observed early in diabetes. Venules may influence arteriolar constriction and flow; therefore, we hypothesized that diabetes would induce the constriction of arterioles that are in close proximity to venules, with the constriction mediated by thromboxane and angiotensin II. Using nonobese diabetic (NOD) mice, retinal measurements were performed three weeks following the age at which glucose levels exceeded 200 mg/dL, with accompanying experiments on age-matched normoglycemic NOD mice. The measurements included retinal arteriolar diameters and red blood cell velocities and were repeated following an injection of the thromboxane synthase inhibitor, ozagrel. Mice were subdivided into equal groups and given drinking water with or without the angiotensin II receptor antagonist, losartan. Retinal arterioles were constricted in hyperglycemic mice, with a significant reduction in flow. However, not all arterioles were equally affected; the vasoconstriction was limited to arterioles that were in closer proximity to venules. The arteriolar vasoconstriction (mean arteriolar diameters = 51 +/- 1 vs. 61 +/- 1 microm in controls; p < 0.01) was eliminated by both ozagrel (61 +/- 2 microm) and losartan (63 +/- 2 microm). Venule-dependent arteriolar vasoconstriction in NOD mice is mediated by thromboxane and/or angiotensin II.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ozagrel hydrochloride hydrate, ≥98% (HPLC), solid